Monthly Archives: August 2018

http://www.lslog.com/express-scripts-bars-48-drugs-for-2019-hitting-abbvie-gilead-boehringer-and-more/Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more

Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more

Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more It’s that time of year again—the time when lead pharmacy benefits manager Express Scripts ignites pharma’s ire […]

http://www.lslog.com/with-patisiran-launch-in-its-sights-alnylam-plots-a-major-hiring-spree/With patisiran launch in its sights, Alnylam plots a major hiring spree

With patisiran launch in its sights, Alnylam plots a major hiring spree

With patisiran launch in its sights, Alnylam plots a major hiring spree Alnylam’s first drug approval could come any day now, and the company is bulking up to get ready—in […]

http://www.lslog.com/fda-notes-paratek-antibiotics-noninferiority-as-it-heads-to-adcomm-vote/FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote

FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote

FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote Paratek Pharmaceuticals’ first drug, and the first in a new class of broad-spectrum antibiotics called aminomethylcyclines, has shown to […]

http://www.lslog.com/akouos-raises-50m-to-take-hearing-loss-gene-therapy-into-humans/Akouos raises $50M to take hearing loss gene therapy into humans

Akouos raises $50M to take hearing loss gene therapy into humans

Akouos raises M to take hearing loss gene therapy into humans Akouos has raised $50 million to take a gene therapy treatment for hearing loss into the clinic. The Boston-based […]

http://www.lslog.com/ironwood-abandons-deal-with-astrazeneca-for-lesinurad-once-hoped-to-be-a-gout-blockbuster/Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster

Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster

Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster Ironwood Pharmaceuticals has decided to walk away from its 2016 deal to license AstraZeneca’s billion-dollar gout […]

http://www.lslog.com/ironwood-dumps-astrazeneca-gout-drug-zurampic-and-lays-off-125-in-the-process/Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the process

Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the process

Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the process Zurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound […]

http://www.lslog.com/acorda-inks-ampyra-generic-settlements-as-it-waits-for-patent-appeal-news/Acorda inks Ampyra generic settlements as it waits for patent appeal news

Acorda inks Ampyra generic settlements as it waits for patent appeal news

Acorda inks Ampyra generic settlements as it waits for patent appeal news Late last month, a court refused to block copies of Acorda’s Ampyra leading up to a patent appeal […]

http://www.lslog.com/mayo-clinic-pinpoints-genes-that-raise-the-risk-of-triple-negative-breast-cancer/Mayo Clinic pinpoints genes that raise the risk of triple-negative breast cancer

Mayo Clinic pinpoints genes that raise the risk of triple-negative breast cancer

Mayo Clinic pinpoints genes that raise the risk of triple-negative breast cancer The ability to identify women who face the highest risk of triple-negative breast cancer could save lives, but […]

http://www.lslog.com/janssen-bayer-to-close-south-korean-plants-due-to-limited-demand/Janssen, Bayer to close South Korean plants due to limited demand

Janssen, Bayer to close South Korean plants due to limited demand

Janssen, Bayer to close South Korean plants due to limited demand Janssen and Bayer are joining a long list of pharma companies closing their manufacturing facilities in South Korea. And […]

http://www.lslog.com/allergan-preludes-major-selloffs-with-650m-almirall-dermatology-sale/Allergan preludes major selloffs with $650M Almirall dermatology sale

Allergan preludes major selloffs with $650M Almirall dermatology sale

Allergan preludes major selloffs with 0M Almirall dermatology sale Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land. […]